ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

168
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
03 Mar 2024 20:53

China Healthcare Weekly (Mar.1) - Prioritize Big Pharma, Real Ownership of Pricing Power, Hengrui

Investors should prioritize pharmaceutical companies with abundant cashflow/diversified funding sources.Pricing power has never belonged to any...

Logo
366 Views
Share
bearishTYK Medicines
01 Mar 2024 08:55

Pre-IPO TYK Medicines - Survival Risk Is Imminent, with Limited Highlights in the Pipeline

Except TY-9591 for brain metastases from NSCLC, the rest pipeline has little highlight but with fierce competition.As a biotech with no...

Logo
535 Views
Share
21 Feb 2024 23:19

China Traditional Chinese Medicine (570 HK): Sinopharm-Led Pre-Conditional Offer at HK$4.60

The offer is attractive to historical trading ranges and peer multiples. Ping An, which holds a blocking stake, will be supportive. This looks like...

Logo
496 Views
Share
07 Feb 2024 22:14

China Traditional Chinese Med (570 HK): Third Time's the Charm as Sinopharm Revives Its Interest?

Due to Sinopharm's previous privatisation attempts, shareholders will be wary of the latest rumour. Nevertheless, the valuation is undemanding...

Logo
372 Views
Share
bullishChina Mobile
15 Jan 2024 09:20

HK Connect SOUTHBOUND Flows (To 12 Jan 2024); High Div SOEs Still the Biggest Buys

SOUTHBOUND saw large net buying of High-Div SOEs. Again. Many weeks in a row now and in terms of % of volume, the mobile phone cos rank high. ETFs...

Logo
322 Views
Share
x